MORRIS TOWNSHIP, N.J. – Honeywell (NYSE:HON) announced today the introduction of a new RNA reagent for use in developing advanced therapeutic medicines.

The new product, the Burdick & Jackson rBMI activator, is designed to help laboratories reduce the use of costly amidites, critical ingredients used in the process of making RNA-based medicines, without reducing RNA yield from the process.

The patented formulation is also blended to help the activator remain stable in cold temperatures, which ensures that laboratories will have a product that can be reliably shipped, stored, and handled during the winter months.

“Our new rBMI activator is formulated to help labs develop therapeutic medicines in a more efficient and productive way,” said Jeremy Diringer, marketing manager for Honeywell Burdick & Jackson. “As with all BioSyn products, this activator maintains the high level of purity that the pharmaceutical industry has come to expect from Burdick & Jackson for more than five decades.”

Honeywell’s rBMI activator is an extension of the Burdick & Jackson BioSyn® line of high-purity DNA and RNA reagents, which are key components in the development of new therapeutic medicines to treat cancer, diabetes, and many other diseases.

The new reagent, consisting of a BMT-type activator, reduces the amount of amidites needed for RNA synthesis without sacrificing the yield of the synthesis, when compared with ETT-type activators. The activator is blended with NMI, a substance that helps to improve the solubility of the formulation. As with all BioSyn reagents, the rBMI activator has low water content for moisture-sensitive applications.

BioSyn DNA and RNA solvents and reagents are engineered to meet the high purity and consistency standards that the pharmaceutical industry requires. A wide range of packaging options, from glass bottles to bulk containers, are available to meet laboratory or production needs.

Honeywell Burdick & Jackson has provided high-quality research chemicals and supplies to the chemical and pharmaceutical industries for more than 50 years. It maintains laboratories and production facilities in Muskegon, Michigan. To learn more about Burdick & Jackson products and access the online product outlet, visit www.burdickandjackson.com.

Honeywell Specialty Materials is a global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London, and Chicago Stock Exchanges. For more news and information on Honeywell, please visit www.honeywellnow.com.

This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address activities, events or developments that we or our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this release are also subject to a number of material risks and uncertainties, including but not limited to economic, competitive, governmental, and technological factors affecting our operations, markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by such forward-looking statements.